Ethiodised oil

Drug Profile

Ethiodised oil

Alternative Names: Ethiodol; Lipiodol

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial source
  • Developer Guerbet
  • Class Antineoplastics; Contrast media; Diagnostic agents; Infertility therapies
  • Mechanism of Action Diagnostic imaging enhancers; Tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer metastases; Hepatocellular carcinoma; Lymphoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Sep 2015 Guerbet signs an agreement with Beijing Ke Yuan Xinhai Pharmaceuticals to distribute and commercialise Ethiodised oil (Lipiodol®) in China
  • 10 Apr 2014 Registered for Hepatocellular carcinoma (diagnosis) and Diagnostic imaging in USA (Intrahepatic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top